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ABSTRACT
Recurrent fetal losses indicate screening for antiphospholipid antibodies, especially after the third
consecutive fetal loss, or when they occur after 12 weeks gestation or when the mother presents
with thrombosis or other ailments of antiphospholipid syndrome. Fetal loss may be caused by
thromboses of placental vasculature. There is no agreement concerning the mechanism of throm-
boses: protein C pathway and/or annexin V are the best candidates. When fetal loss occurs early
during gestation, murine models suggest that antiphospholipid antibodies can also act on tropho-
blasts by inhibiting syncytia formation. Among the high risk patients with more than two fetal
losses, an association of aspirin and heparin given early during gestation is successful in 70-80% of
cases. Infect. Dis. Obstet. Gynecol. 5:183-191, 1997. (C) 1997Wiley-Liss, Inc.
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ecurrent fetal loss (FL) affects 1-5% ofwomen
of childbearing age. 1,z Chromosomal abnor-
malities account for 60% of recurrent FL. Immu-
nological mechanisms may account for the remain-
ing 40%, and in particular, the antiphospholipid
syndrome (APLS) appears to be implicated in 7-
25% of recurrent FL.z
In 1980, Soulier and Boffa3 suggested a relation-
ship between recurrent FL and lupus anticoagulant
(LA). The APLS was defined 7 years later4 based
on a combination of clinical and biological abnor-
malities: on the one hand, venous or arterial throm-
bosis and/or recurrent FL; on the other, recurrent
evidence of LA and/or anticardiolipin antibodies
(ACL). Objections may be raised to this defini-
tion,5 one of the major problems being the inter-
laboratory variation in ACL assays and the absence
of consensus concerning the normal upper limit of
ACL.6 In our laboratory, we consider the normal
upper limit to be 20 GPL units for IgG ACL and 20
MPL units for IgM ACL.
Antiphospholipid-associated obstetrical disor-
ders are not limited to FL. They also include in-
fertility, intrauterine growth retardation, fetal dis-
tress, prematurity,7 and in the mother, preeclamp-
sia8 and chorea gravidarum.
9 We shall limit
ourselves to FL, a term including abortion and fetal
death, the limit between these being considered by
Branch1 to be at 20 weeks gestation.
WHEN TO SCREEN FOR
ANTIPHOSPHOLIPID ANTIBODIES (APL)?
It is generally considered that screening for APL is
unnecessary in asymptomatic gravida 0 or nullipa-
rous women. 11-3 Indeed, LA and ACL positivity
are infrequent in these women, being present in
less than 4%, and the relationship to the outcome
of pregnancy is unclear. However, the findings of
Lynch et al. 14 are conflicting, with a 24.4% PL
positivity rate among nearly 400 nulliparous pa-
tients, and a 2.44 relative risk of FL among APL-
positive women.
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TABLE I. APL frequency in FL
Results (%)
Author LA ACL (IgG)
One FL
Two FL
Three FL
Infante-Rivard et al., 1991 s 3.8 1.5
Cowchock et al., 1986
6 13
Edelman et al., 198617 14
Howard et al., 1987 48
Petri et al., 1987 9 II
Unander et al., 1987
9 35
Creagh et al., 199120 20 17
Parke et al., 1991
3 4.5 6.8
Rai et al., 19552s 9.1 3.3
Screening for APL also seems unjustified after a
first FL. The case-control study conducted by In-
fante-Rivard et al. is with 331 patients and 993 con-
trols showed 5.1% LA positivity in patients vs.
3.8% in controls (relative risk:l.42) and 1.2% IgG
ACL positivity in patients vs. 1.5% in controls.
On the other hand, screening becomes cost ef-
fective after two, or better, three FL.13’6-z The
problem is that the percent APL positivityin these
patients varies widely in different studies. Table
shows an LA variation from 4.5% to 48%, and the
percent IgG ACL positivity varies from 6.8% to
35%. There is generally a significant difference be-
tween patient and control groups, except in the
study by Petri et al.z In this study, the difference
between a group of 44 patients with recurrent FL
and a group of 40 controls was not significant; how-
ever, a number of questions can be raised about
this study: the sensitivity of the method used for
LA testing (using the dilute Russell’s viper venom
time) is probably too low, and the study population
is not large enough to detect a significant differ-
ence (9% LA positivity in patients vs. 0% in con-
trols, and 11% ACL positivity in patients vs. 2.5%
in controls); moreover, in this study, more than
50% of patients had very early miscarriages.
Apart from the number of FL, other criteria
should be taken into account, especially the date of
the FL. Within a pregnancy, the first 12 weeks of
gestation (the preembryonic and embryonic peri-
ods) should be distinguished from the following
weeks which are, strictly speaking, the fetal period.
According to Branch et al,zz whose experience of
FL is quite extensive; FL occurs within the first 12
weeks of gestation in nearly half of cases, and in
the other half, mostly between 16 and 20 weeks
gestation. However, in several large studies, espe-
cially in a number of recent randomized therapeu-
tic trials, pretreatment FL occurred mostly during
the first trimester,z3-zs In Kutteh’sz4 study, 80% of
pretreatment FL occurred before 12 weeks gesta-
tion. In any case, the occurrence of FL after 12
weeks gestation rules out a syndrome of recurrent
early pregnancy loss, or intrauterine embryonic
death, ,z6 which always occurs before 12 weeks ges-
tation and is not associated with detectable anti-
bodies in the mother, and might be due to antitro-
phoblast natural killer (NK) cell toxicity,z7
The inevitable occurrence of FL in all subse-
quent pregnancies in women who have experi-
enced one FL is also a strong argument for testing
for APL. Lubbe and Ligginszs and Branch et al.z9
have convincingly demonstrated that there is a
group of high risk patients whose pregnancies ter-
minated in FL in more than 90% of cases. A per-
sonal study of 22 patients showed FL in 50% of
LA-positive patients, but after this first FL, subse-
quent pregnancies also ended up in FL in 23 of 24
cases.3o
The occurrence of thrombosis in the mother
during, or above all, immediately after preg-
nancy
31-33 is also an argument for screening for
APL, and besides, two of three patients in Soulier
and Boffa’s3 original description had had a history
of thrombosis. However, the association ofFL with
thrombosis can also be due to a congenital coagu-
lation disorder, especially resistance to activated
protein C (APCR). In Brenner et al.,4 a Leiden
mutation of factor V was present in 19 of 39 pa-
tients. The problem becomes more difficult in that
acquired APCR without a Leiden mutation was
present in 9 of 39 patients, and as is well known,
APL can induce APCR.3s,36 Apart from thrombosis,
the other factors of the APL are also very sugges-
tive (Table 2); early preeclampsia (at approxi-
mately 30 weeks gestation) or placental abruption,
would also indicate screening for APL.7
In the specific case of systemic lupus erythem-
atous (SLE), FL is associated with APL positivity,
as demonstrated in particular by Derksen et al.37
for LA and Deleze et al.38 for ACL. The prospec-
tive study by Petri et al.39 showed that only second
trimester FL appears to be associated with APL
positivity. In any case, ACL screening is mandatory
in all SLE patients considering pregnancy (in the
same way as testing for anti-SSA/SSB antibodies).
Lastly, placental histology may suggest an APL
syndrome in the first FL if it demonstrates the
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TABLE 2. Clinical manifestations associated
with APL
Obstetrical
Recurrent FL
Intrauterine growth retardation
Infertility
Preeclampsia
Placental abruption
Vascular
Venous thrombosis
Arterial thrombosis
Neurological
Transient cerebral ischemic attacks
Stroke
Epilepsy
Chorea
Multi-infarct dementia
Cardiac
Mitral and aortic valve disease
ntracardiac thrombosis
Myocardial infarction
Cardiomyopathy
Dermatological
Skin necrosis
Livedo reticularis
Subungual hemorrhage
Leg ulcers
Miscellaneous
Renal failure
Budd-Chiari syndrome
Hypertension
Pulmonary hypertension
presence of numerous placental thromboses. Evi-
dence of such thromboses was reported by Nilsson
et al.4 as early as 1975 and was confirmed in sub-
sequent pathological studies.41-43 Such patients
must be screened for APL in the same way as for
congenital anomalies (especially APCR).
WHICH APL IS THE BEST MARKER FOR FL?
In APLS, treponema serology is usually negative
(88% of negativity in a personal series of 25 pa-
tients); when VDRL gives a false-positive, it is a
reliable marker of FL. Thornton et al.44 estimated
the relative risk of FL to be 28.5 in these circum-
stances.
According to Derksen et al.37 and Petri and All-
britton,4s LA is the best marker of FL. Derksen et
al.37 report 75% FL in patients with SLE testing
positive for LA vs. 19% in those testing negative.
Petri and Allbritton4s found LA in 40% of lupus
patients with FL and 26% of lupus patients achiev-
ing full-term pregnancies.
According to other authors,46 ACL is the best
predictive factor for FL, but this finding should be
qualified. The risk increases as ACL levels in-
crease.47,48 Persistence ofACL positivity is particu-
larly important;49 transitory ACL positivity has
practically no diagnostic value,s In SLE patients,
the relative risk of FL is 10 in ACL-positive pa-
tients compared with ACL-negative patients)s
Aoki et al.sl demonstrate that among APLS, the
incidence of antibodies to anionic beta 2 GPl-
dependent phospholipids appears to be higher in
patients who have had FL. However, when testing
patients with APLS at risk for thrombosis, anti-beta
2 GP1 appears to be less sensitive than LA. Com-
mercially available kits for global screening ofAPL
also appear to have low sensitivity. In a personal
study of 25 patients with ALPS and ACL, the sen-
sitivity of screening with BMD kits was only 76%,
and this test did not detect two of ten patients with
recurrent FL syndrome. In the event of negative
findings with the standard laboratory tests, in the
context of highly suggestive clinical findings,
screening for antibodies to anti-beta 2 GPl, or to
neutral phospholipid such as phosphatidylethanol-
amine, is justified,sz
In practice, evaluation of LA and ACL initially
and at 8 weeks should be recommended in patients
with a suspicion of APLS. In clinically suggestive
cases with negative laboratory findings, it is justi-
fied to also test for false-positive VDRL, anti-beta
2 GPl, and antiphosphatidylethanolamine.
MECHANISM OF FL
Additional evidence of the relationship between
APL and FL is shown with experimental models,s
These models lead us to the investigation of the
precise mechanism of FL.
1. Pathological findings show numerous placen-
tal infarcts in these patients,4,41,4 suggesting that
FL might be caused by thrombosis of the placental
vasculature. There is no agreement as to the
mechanism causing these thromboses. A fibrinolyt-
ic disorder, inhibition of prostacyclin formation by
vascular walls,s4 and a disorder of the protein C
pathwayss have successively been mentioned, and,
more recently, an interaction between APL and
annexin V.s6 The two latter hypotheses are the
most convincingly documented.
As far as the protein C pathway is concerned, the
presence of an acquired deficit of free protein S
appears to be established in both APLS secondary
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TABLE 3. Available therapeutic trials: antithrombotic drugs
Authors
No. of patients
(No. of pregnancies) Results
Aspirin
Heparin
Aspirin + heparin
Omega 3 fatty acids
Sanchez-Guerrero and Alarcon-Segovia, 199266
Rosove et al., 199023
Kutteh, 199624
Rai et al., 199725
Rossi and Costa, 1993
7(9) 5 LBa,2FL
14 (15) 14 LB, FL
25 aspirin 44% LB
25 aspirin + heparin 80% LB
45 heparin 42% LB
45 aspirin + heparin 71% LB
22 21 LB, FL
aLB live birth.
to SLE and in primary APLS.s7-s9 APLS have also
been shown to induce an APCR36 without muta-
tion of factor V, which can be corrected by the
addition of platelet extracts.3s Inhibition of protein
C activation by thrombomodulin is much more hy-
pothetical,ss
Concerning the action of APL on annexin V,
Rand et al.s6 have recently compared three patients
with recurrent FL to three controls. Levels of an-
nexin V on the surface of trophoblastswere re-
duced in the presence of IgG APL of patients com-
pared to controls; the coagulation time of plasma in
contact with trophoblasts was also longer in the
presence of IgG APL patients. This implies that
the usual cascade sequence for blood coagulation is
physiologically inhibited by the annexin V depos-
ited on the surface of trophoblasts and that APLs
interfere with annexin V, preventing it from depos-
iting on the membrane of trophoblasts.
2. In vitro studies suggest that APLs also act on
trophoblasts at a very early stage by inhibiting syn-
cytia formation.6 Murine models have demon-
strated that mice immunized by IgG ACL have low
fertility and high fetal resorption rates.61 This ac-
counts for the high rate of first trimester FL and
suggests that therapy should be initiated very early,
even before fertilization.6e
THERAPEUTIC MANAGEMENT
Considerable advances have been made since 1983
when Lubbe et al.,6 in New Zealand, demon-
strated that administration of steroids and low dose
aspirin resulted in live births in practically all pa-
tients in a small group with a very high risk of FL.
The first question to be addressed is at what
point treatment should be initiated, i.e., starting
with which pregnancy, and at what time in the
pregnancy. If the APLS is diagnosed because of
FL, a complete workup, particularly immunologi-
cal, should be carried out certainly by the third
pregnancy, and APL positivity confirmed. In prac-
tice, this workup is often initiated after the second
FL. Therefore, the patient will initially be treated
at her third or fourth pregnancy. It seems logical to
start treatment as soon as pregnancy is confirmed,
since it has been shown that APL may inhibit the
development of trophoblasts, thus inducing very
early FL.
If APL positivity has been established before
the first pregnancy, for instance in a SLE patient
presenting with thrombosis, or even in an asymp-
tomatic woman being operated or before she gets
married, and if the patient is given no drug when
she gets pregnant, in principle it would be possible
to give her no treatment since such a patient is
known to have a in 2 chance of a full-term preg-
nancy despite APL positivity. However, routine
administration of aspirin (50-150 mg daily) starting
from this first pregnancy seems advisable, since
such therapy has been shown to be harmless for
both the fetus and the mother.64’6s
What methods are available? In the 1980s, im-
munomodulant therapy was favored, but it is cur-
rently supplemented with antithrombotic therapy.
Antithrombotic Drugs
Several studies, some open, some randomized,66’67
have demonstrated that full-term pregnancies
could be achieved with aspirin alone, even in pa-
tients with a long history of FL (Table 3). In a
study by Silver et al.,67 the success rate with aspirin
alone was 100%, but it should be noted that some
patients had suffered only one FL at inclusion. On
the other hand, a study of 15 pregnancies in 14 high
risk women by Rosove et al.e showed a 93% suc-
cess rate (14 live births in 15 pregnancies) with
subcutaneous unfractionated heparin at therapeu-
tic dosage starting from the 10th week of prey-
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TABLE 4. Available therapeutic trials: Immunomodulant plus antithrombotic drugs
No. of patients
Authors (No. of pregnancies) Results
Steroids + aspirin
Immunoglobulins + aspirin + heparin
Plasma exchanges
Lubbe et al., 198363 7 6 LBa, FL
Branch et al., 198529 8 5 LB, 3 FL
Lockshin et al., 1989TM 21 7 LB, 14 FL
Silveira et al., 199273 (12) 12 LB, 0 FL
Laskin et al., 19977s 46 placebo 52% LB
42 steroids + aspirin 60% LB
Spinnato et al., ]9958 5 5 LB, 0 FL
Frampton et al., 198782 LB
Fucher et al., 198983 LB
aLB live birth.
nancy. A posteriori confirmation of the efficacy of
heparin was given in 1993 by Inbar et al.68 in a
murine model.
Two recent studies demonstrated that combina-
tion therapy with low dose aspirin and heparin was
more efficient than aspirin alone. In Kutteh’s24
study of 50 patients, after the diagnosis of preg-
nancy had been confirmed, heparin was given to 25
patients at therapeutic dosage to the end of preg-
nancy. Success rate was 44% in the group receiving
aspirin alone and 80% in the group receiving aspi-
rin plus heparin. In Rai et al.’s2 randomized study
of 90 patients, low dose heparin (5,000 units) was
started only when an ultrasound scan showed evi-
dence of fetal heart activity, and it was stopped if
an FL occurred, or otherwise at 34 weeks gestation.
Success rate was 42% in the group on aspirin and
71% in the group on aspirin plus heparin. The risk
of osteoporosis associated with heparin therapy
given to patients during their entire pregnancy
should be mentioned,69-71 and it is worth noting
that Rai et al.2s showed a 5.4% decrease of lumbar
bone density postnatally.
Lastly, Italian researchers72 treated 23 pregnan-
cies in 22 patients with high dose omega 3 fatty
acids alone (18 capsules daily, whereas the recom-
mended dosage is 6 daily). The success rate was
dramatic: 22 live births in 23 pregnancies (96%). It
is unclear whether the antiaggregant action of fish
oils alone was involved, or if another mechanism
should be considered.
Immunomodulant Drugs
This treatment aims to reduce APL levels. Steroids
and high dose intravenous immunoglobulins
(IVIg) have been used successively, and alsom
anecdotallymplasma exchanges. In fact, these
therapies have practically always been combined
with antithrombotic drugs, so that their specific ef-
ficacy cannot be readily assessed (Table 4).
Lubbe et al.63 in 1983 and Branch et al.z9 in
1985 must be credited with demonstrating that in
small (fewer than 10) groups of patients at very
high risk of FL, administration of steroids and as-
pirin resulted in live births in most cases. Subse-
quent findings are conflicting. According to Silveira
et al.73 this combination is very efficacious. Accord-
ing to Lockshin et al.,74 it is not. In Lockshin et
al.’s74 study, 14 FL occurred in 21 pregnancies, but
it should be noted that the dosage of steroids was
not standardized and it was tapered rapidly during
the pregnancy. In a recent randomized study by
Laskin et al.,75 the combination of steroids and as-
pirin was no better than placebo, but in this study
APL-positive patients were mixed with patients
testing positive for antinuclear antibodies only. If
only APL-positive patients are taken into account,
the success rate is 60% in the group receiving ste-
roids and aspirin and 52% in the placebo group.
However, it should be noted that the success rate
in the placebo group is considerable, while it is
admitted that less than 10% full-term pregnancies
are achieved in high risk patients,z8,z9 In a personal
non-randomized series including 27 LA-positive
patients who had experienced several FL, 8 pa-
tients were given steroids alone and 19 patients
steroids plus aspirin. The success rate was 3 of 8
(37.5%) in the group on steroids alone, and 10 of 19
(53%) in the group on steroids plus aspirin. The
numbers were too small to reach significance. In
this study, LA negativation was a good predictor of
favorable outcome (68% live births in the subset of
those who became LA-negative patients).
IVIg therapy has been successfully tested in at
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TABLE 5. Available therapeutic trials: antithrombotic + immunomodulant drugs
Authors No. of patients Results
Silver et al., 199367 22 aspirin 22 LB 0 FL
12 aspirin + steroids 12 LB, 0 FL
Cowchock et al., 199284 8 aspirin + steroids 6 LB, 2 FL
12 aspirin + heparin 9 LB, 3 FL
Aspirin + steroids
Aspirin + steroids or heparin
aLB live birth.
least 12 reports in the literature,76-8z but in all cases
aspirin and/or heparin and/or steroids.were com-
bined. We have used IVIg in three cases after fail-
ure of standard steroid plus aspirin treatment, suc-
cessfully in all three. In one case, the outcome was
satisfactory in spite of increasing ACL and beta 2
GP1 antibodies increasing again at the end of preg-
nancy.
Two reports of the efficacy of plasma exchanges
have been published.8z,83
Combination Therapies (Antithrombotic and/or
Immunomodulant Drugs)
At least two randomized studies have compared
steroids and antithrombotic drugs (Table 5). In the
study by Silver et al.67 mentioned above, the out-
come was dramatic in the group on aspirin alone (N
22) and in the group on aspirin plus steroids (N
12) since no FL occurred in either group. However,
patients could be included after a single FL and 5
of 17 initially randomized patients in the aspirin
plus steroids group were not evaluated. A random-
ized study by Cowchock et al.84 compared heparin
with steroids in a small group of 20 patients who
also received aspirin; success rate was 75% in each
group. In both studies,67,84 premature deliveries
were more frequent in patients who received ste-
roids.
Therapeutic Strategies
In women with a history of at least three FL, a
minimal immunological workup (antinuclear anti-
bodies, IgG ACL, LA) seems advisable. In prac-
tice, this is often done after only two FL. The
initial intervention may include aspirin alone, 50-
150 mg daily. After failure of this therapy, or if
three FL have already occurred and if the patient is
relatively old, aspirin and heparin may be pre-
scribed from the beginning of pregnancy. We con-
sider that the choice of a therapeutic dose of hep-
arin administered in two subcutaneous injections is
justified. Low molecular weight heparins are not
licenced in France during pregnancy, but they
have proved to be harmless in studies conducted in
France and elsewhere. Laboratory follow-up dur-
ing pregnancy includes at least a complete blood
count (CBC), lactate dehydrogenase (LDH), hap-
toglobin and reactive protein, creatinine and uric
acid, and transaminases (so that a HELLP syn-
drome is not missed). Fetal ultrasound scan with
Doppler studies of the uterines and umbilical ar-
teries are recommended from 22 weeks gestation;
Doppler study of the uterine arteries is performed
as early as 15 or 16 weeks gestation by some teams.
Aspirin should be stopped at 35 or 36 weeks ges-
tation, so that it has been withdrawn for at least 1
week when epidural anesthesia is performed. At
that stage, aspirin should be replaced with two
daily injections of low molecular weight heparin; if
the patient was already on heparin, this treatment
should be continued. Heparin should be inter-
rupted for as short a period as possible at the time
of delivery. These precautions are mandatory in
patients with a history of thrombosis. Strokes have
been observed in the immediate postpartum period
in patients in whom all antithrombotic drugs had
been withdrawn.32
In the event of failure of combined aspirin plus
heparin therapy, treatment with aspirin plus ste-
roids 0.5 mg/kg/day, or even with aspirin plus ste-
roids plus heparin, should be administered. Should
this treatment fail, further treatment may include
IVIg, bearing in mind that it implies a course of
treatment every 20-30 days to the end of preg-
nancy.
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